Stock Analiz

Ovid Therapeutics Inc. OVID

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$2.54Market cap $479M
Open the interactive analysis →

Ovid Therapeutics Inc. (OVID) is a healthcare company listed in the US with a market value of about $479M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$43M, a net margin of -2971.3%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -10% a year, a 5-year average ROIC of -26%.

About Ovid Therapeutics

Ovid Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $13M in 2020 to $7M in 2025, a decline of about 10.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 168% over three years (dilution for shareholders). It spends 353% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S330.4
P/B2.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-12.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)1181.3%
Revenue growth (5 yrs, per year)-10.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4361.5%
ROIC (5-yr avg.)-26.0%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1M$7M$566000$392000$2M$208M$13M————
Net income-$43M-$17M-$26M-$52M-$54M$123M-$81M-$60M-$52M-$65M-$22M
Free cash flow-$58M-$38M-$56M-$46M-$56M$118M-$52M-$51M-$46M-$32M-$18M
EPS (diluted)$-0.28$-0.09—$-0.74$-0.77$1.76$-1.39—$-2.11$-3.35$-2.28
Net margin-2971.3%-240.1%-4670.1%-13351.8%-3604.7%59.0%-642.3%————
ROIC—-29.5%-74.6%-57.1%-37.3%68.4%-186.6%-69.3%-107.8%-61.6%-36.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $6.15, 142% above the current price; targets range from $4.00 to $9.00; the consensus rating is “Strong buy”; expected EPS is $-0.40 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Ovid Therapeutics pay a dividend?

Not currently.

Is Ovid Therapeutics a good stock to buy?

We do not give buy or sell advice. Ovid Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.